Malaria Vaccines remain one of the most essential vaccines with limited options

Posted by coherent market insights on January 25th, 2021

A malaria vaccination is a live attenuated vaccine that effectively prevents malaria from causing disease in humans. Currently, the only approved malaria vaccine as of late is RTS, which is marketed by the pharmaceutical company GlaxoSmithKline. It has very low efficiency and takes four separate injections. This type of vaccine has not been shown to have any benefit in preventing malaria in children. There have been several clinical trials involving malaria vaccines. Although most were successful, there was one trial that did not show any efficacy for preventing illness. There are now two vaccines in development, the first being the project titled Glanzbug and the second edition of Salk's Preventive Therapy portfolio, or TTP.

The U.S. government has set up a program called MDA - the Vaccine Adversus Control Project, which aims to control and monitor the safety and effectiveness of all new malaria vaccines. For children who participate in the clinical trials, this is important because their immunity may decline with time. There are also ongoing phase I and II clinical trials. In the initial stages of development, there are no guarantees of efficacy, so no investment bank or insurance company will foot the bill. Phase I trials measure the safety and efficacy of malaria vaccines. If it works well, it goes into phase II, which involves testing to see how well it interacts with the local environment. If it does not work well, it goes back to the drawing board.

ReadMore@https://www.linkedin.com/pulse/malaria-vaccines-remain-one-most-essential-limited-options-shinde